```
=>
=> d his

     (FILE 'HOME' ENTERED AT 13:36:15 ON 07 JUL 2010)

     FILE 'REGISTRY' ENTERED AT 13:36:20 ON 07 JUL 2010
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           43 S L1 SSS FUL
L4           32 S L3 AND CAPLUS/LC
L5           11 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 13:36:51 ON 07 JUL 2010
L6            4 S L3

=> d ibib abs hitstr total
```

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:151735 CAPLUS
DOCUMENT NUMBER: 148:426806
TITLE: New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems
AUTHOR(S): Micheli, Fabrizio; Bonanomi, Giorgio; Braggio, Simone; Capelli, Anna Maria; Celestini, Paolo; Damiani, Federica; Di Fabio, Romano; Donati, Daniele; Gagliardi, Stefania; Gentile, Gabriella; Hamprecht, Dieter; Petrone, Marcella; Radaelli, Stefano; Tedesco, Giovanna; Terreni, Silvia; Worby, Angela; Heidbreder, Christian
CORPORATE SOURCE: Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Verona, 37135, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(3), 901-907
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:426806

AB The synthesis and SAR of a new series of potent and selective dopamine D3 receptor antagonists is reported. The introduction of a tricyclic [h]-fused benzazepine moiety on the recently disclosed scaffold of 1,2,4-triazol-3-ylthiopropyltetrahydrobenzazepines is reported. A full rat pharmacokinetic characterization is also reported.

IT 871541-86-5P 1016976-88-7P 1016976-89-8P
1016976-90-1P 1016976-91-2P 1016976-92-3P
1016976-93-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of triazolylalkylbenzazepines as dopaminergic D3 antagonists)

RN 871541-86-5 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 1016976-88-7 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 10-bromo-6,7,8,9-tetrahydro-2-methyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 1016976-89-8 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 10-bromo-2-ethyl-6,7,8,9-tetrahydro-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 1016976-90-1 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 10-bromo-6,7,8,9-tetrahydro-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 1016976-91-2 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2,10-dimethyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 1016976-92-3 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 2-ethyl-6,7,8,9-tetrahydro-10-methyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 1016976-93-4 CAPLUS
CN 5H-Oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-10-methyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-2-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1034144 CAPLUS
DOCUMENT NUMBER: 147:397855
TITLE: 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists
AUTHOR(S): Micheli, Fabrizio; Bonanomi, Giorgio; Blaney, Frank E.; Braggio, Simone; Capelli, Anna Maria; Checchia, Anna; Curcuruto, Ornella; Damiani, Federica; Di Fabio, Romano; Donati, Daniele; Gentile, Gabriella; Gribble, Andy; Hamprecht, Dieter; Tedesco, Giovanna; Terreni, Silvia; Tarsi, Luca; Lightfoot, Andrew; Pecoraro, Michela; Petrone, Marcella; Perini, Ornella; Piner, Jacqui; Rossi, Tino; Worby, Angela; Pilla, Maria; Valerio, Enzo; Griffante, Cristiana; Mugnaini, Manolo; Wood, Martyn; Scott, Claire; Andreoli, Michela; Lacroix, Laurent; Schwarz, Adam; Gozzi, Alessandro; Bifone, Angelo; Ashby, Charles R., Jr.; Hagan, Jim J.; Heidbreder, Christian
CORPORATE SOURCE: Psychiatry Centre of Excellence, Molecular Discovery Research, and Safety Assessment, GlaxoSmithKline Medicine Research Centre, Verona, 37135, Italy
SOURCE: Journal of Medicinal Chemistry (2007), 50(21), 5076-5089
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:397855
GI



I

AB The discovery of new highly potent and selective dopamine D3 receptor antagonists has recently permitted characterization of the role of the

dopamine D3 receptor in a wide range of preclin. animal models. A novel series of 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines demonstrating a high level of D3 affinity and selectivity with an excellent pharmacokinetic profile is reported here. In particular, the pyrazolyl derivative 35 (I) showed good oral bioavailability and brain penetration associated with high potency and selectivity in vitro. In vivo characterization of 35 confirmed that this compound blocks the expression of nicotine- and cocaine-conditioned place preference in the rat, prevents nicotine-triggered reinstatement of nicotine-seeking behavior in the rat, reduces oral operant alc. self-administration in the mouse, increases extracellular levels of acetylcholine in the rat medial prefrontal cortex, and potentiates the amplitude of the relative cerebral blood volume response to d-amphetamine in a regionally specific manner in the rat brain.

IT 865089-89-0P 865089-90-3P 865089-91-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(triazolyl thiopropyl tetrahydrobenzazepines as selective dopamine D3 receptor antagonists)

RN 865089-89-0 CAPLUS
CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 865089-90-3 CAPLUS
CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-91-4 CAPLUS
CN 1H-3-Benzazepine, 3-[2-[[5-(3,4-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1314254 CAPLUS
DOCUMENT NUMBER: 144:51588
TITLE: Preparation of fused benzazepines having affinity for dopamine D3 receptor
INVENTOR(S): Bonanomi, Giorgio; Damiani, Federica; Gentile, Gabriella; Hamprecht, Dieter Wolfgang; Micheli, Fabrizio; Tarsi, Luca; Tedesco, Giovanna; Terreni, Silvia
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118549	A2	20051215	WO 2005-EP5965	20050531
WO 2005118549	A3	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1751163	A2	20070214	EP 2005-756061	20050531
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2008501660	T	20080124	JP 2007-513858	20050531
US 20100016287	A1	20100121	US 2009-569880	20090923
PRIORITY APPLN. INFO.:			GB 2004-12314 A	20040602
			WO 2005-EP5965 W	20050531

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 144:51588; MARPAT 144:51588
GI



I



II

AB The title compds. I [A = 5-6 membered heteroaryl, 5-6 membered heterocyclyl; m = 0-3; R1 = halo, oxo, hydroxy, etc.; R2 = H, Me, Br, etc.; n is not defined; R3, R4 = H, Me; q = 2-4; W1, W2 = N, CH, C(alkyl); R5 = H, alkyl; R6 = alkyl, haloalkyl, Ph, etc.], useful in medicine, for example in the treatment of schizophrenia or drug dependency, were prepared and disclosed. Thus, reacting 2-methyl-6,7,8,9-tetrahydro-5H-[1,3]oxazolol[4,5-h][3]benzazepine and 5-{5-[(3-chloropropyl)thio]-4-methyl-4H-triazol-3-yl}-2-methylquinoline (prepns. given) afforded II.HCl. The exemplified compds. I have pKi values within the range of 7.5-10.0 at the dopamine D3 receptor.

IT 871500-38-8P 871500-39-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused benzazepines having affinity for dopamine D3 receptor)

RN 871500-38-8 CAPLUS

CN 5H-Oxazolo[4,5-h][3]benzazepine, 6,7,8,9-tetrahydro-2-methyl-7-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 871500-39-9 CAPLUS

CN 1,4-Oxazino[2,3-h][3]benzazepine, 2,3,4,6,7,8,9,10-octahydro-8-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-4-

(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT:	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1021748 CAPLUS
DOCUMENT NUMBER: 143:326368
TITLE: Preparation of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors
INVENTOR(S): Arista, Luca; Bonanomi, Giorgio; Damiani, Federica; Hamprecht, Dieter; Micheli, Fabrizio; Tarsi, Luca; Tedesco, Giovanna
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087764	A1	20050922	WO 2005-EP2635	20050304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737851	A1	20070103	EP 2005-715992	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007527890	T	20071004	JP 2007-502302	20050304
US 20080139532	A1	20080612	US 2007-591782	20071121

PRIORITY APPLN. INFO.:	GB 2004-5198	A	20040308
	GB 2004-14204	A	20040624
	WO 2005-EP2635	W	20050304

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:326368; MARPAT 143:326368
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 and R4 independently = H, F, OH, etc.; R2 and R3 independently = halo, CN, NO2, etc.; A and B independently = N or CH; R5-9 independently = H or alkyl; R10 = Z or (CR11R12)nZ; Z = (un)substituted alkyl, haloalkyl, Ph, etc.; R11 and R12 independently = H or alkyl or (CR11R12)n forms a cycloalkylene linker; n = 1-4] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of dopamine D3 receptors. Thus, e.g., II was prepared by subsequent couplings of 7-(5-methyl-3-isoxazolyl)2,3,4,5-tetrahydro-1H-3-benzazepine with chloroacetaldehyde and 4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazole-3-thiol, resp. The activity of I was evaluated using GTPγS

scintillation proximity assay and it was revealed that compds. of the invention displayedpKi values in the range of 7.5 up to 9.5 towards the dopamine D3 receptor. I as modulator of dopamine D3 receptors should prove useful in the treatment of drug dependence. Pharmaceutical compns. comprising I are disclosed.

IT 865089-85-6P 865089-86-7P 865089-87-8P
865089-88-9P 865089-89-0P 865089-90-3P
865089-91-4P 865089-93-6P 865089-95-8P
865089-97-0P 865089-99-2P 865090-01-3P
865090-03-5P 865090-05-7P 865090-06-8P
865090-07-9P 865090-08-0P 865090-09-1P
865090-10-4P 865090-11-5P 865090-12-6P
865090-14-8P 865091-95-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydrobenzazepine derivs. as modulators of dopamine D3 receptors)

RN 865089-85-6 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(4-methyl-5-oxazolyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 865089-86-7 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-87-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-88-9 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-6-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-89-0 CAPLUS

CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-90-3 CAPLUS
CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-91-4 CAPLUS
CN 1H-3-Benzazepine, 3-[2-[[5-(3,4-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 865089-93-6 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865089-92-5
CMF C25 H28 N6 O S



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865089-95-8 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(4-pyridazinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865089-94-7
CMF C23 H25 N7 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 865089-97-0 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-[2-methyl-6-(trifluoromethyl)-3-pyridinyl]-4H-1,2,4-triazol-3-yl]thio]ethyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865089-96-9
CMF C26 H27 F3 N6 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 865089-99-2 CAPLUS
CN Formic acid, compd. with 3-[2-[[5-(5-chloro-1-methyl-1H-pyrazol-4-yl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865089-98-1
CMF C23 H26 Cl N7 O S



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865090-01-3 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-[4-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl]thio]ethyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865090-00-2
CMF C26 H26 F3 N5 O S



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865090-03-5 CAPLUS

CN Formic acid, compd. with 3-[2-[[5-(3,4-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865090-02-4
CMF C25 H25 F2 N5 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 865090-05-7 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865090-04-6
CMF C24 H27 N7 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 865090-06-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(4-methyl-5-oxazolyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-07-9 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-08-0 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-09-1 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-6-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-10-4 CAPLUS
CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-11-5 CAPLUS
CN 1H-3-Benzazepine, 7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro-3-[2-[[4-methyl-5-(5-methyl-2-pyrazinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)



RN 865090-12-6 CAPLUS
CN 1H-3-Benzazepine, 3-[2-[[5-(3,4-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-7-(1,3-dimethyl-1H-pyrazol-5-yl)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865090-14-8 CAPLUS
CN Formic acid, compd. with 2,3,4,5-tetrahydro-3-[2-[[1-(1-methylethyl)-5-(methylsulfonyl)-1H-benzimidazol-2-yl]thio]ethyl]-7-(5-methyl-3-isoxazolyl)-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865090-13-7
CMF C27 H32 N4 O3 S2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 865091-95-8 CAPLUS
CN Formic acid, compd. with 3-[2-[[5-(1,5-dimethyl-1H-pyrazol-4-yl)-4-methyl-4H-1,2,4-triazol-3-yl]thio]ethyl]-2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-1H-3-benzazepine (1:1) (CA INDEX NAME)

CM 1

CRN 865091-94-7
CMF C24 H29 N7 O S



CM 2

CRN 64-18-6
CMF C H2 O2



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2010 ACS on STN
RN 865089-92-5 REGISTRY
ED Entered STN: 12 Oct 2005
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3-[2-[[4-methyl-5-(2-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]thio]ethyl]- (CA INDEX NAME)
MF C25 H28 N6 O S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT